Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The Asthma Control TestTM (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey



To evaluate whether the Asthma Control Test™ (ACT) score is predictive of Global Initiative for Asthma (GINA) guideline-defined classification levels of asthma control. The ACT is a validated, 5-item, patient-completed measure of asthma control with a recall period of four weeks.


Cross-sectional survey comparing ACT score and GINA classification of asthma control among 2949 patients attending primary care physicians and specialists in France, Germany, Italy, Spain, the UK, and the USA.


The area under the receiver operating characteristics curve for ACT score predicting GINA control was 0.84 (95% CI 0.82–0.85). An ACT score of ≤19 (not well-controlled asthma) correctly predicted GINA-defined partly controlled/uncontrolled asthma 94% of the time, while an ACT score of ≥20 predicted GINA-defined controlled asthma 51% of the time, with kappa statistic of 0.42, representing moderate agreement.


An ACT score ≤19 is useful for identifying patients with poorly controlled asthma as defined by GINA.

Author information



Corresponding author

Correspondence to Mike Thomas.

Ethics declarations

Competing interests

Elizabeth V Hillyer has received freelance writing assignments from Merck and Aerocrine. She has no shares in any pharmaceutical company. Professor David Price has consultant arrangements with: Altana, Boehringer-Ingelheim, GlaxoSmithKline, Ivax and Pfizer. He or his team have received grants and research support for research in respiratory disease from the following organisations: UK National Health Service, Altana Pharma, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Ivax, Merck Sharpe and Dohme, Novartis, Pfizer, and Schering Plough. Professor Price has also spoken for: Altana Pharma, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Sharpe and Dohme and Pfizer. Angela E. Williams and Jacqueline R Carranza Rosenzweig are employees of GlaxoSmithKline.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Thomas, M., Kay, S., Pike, J. et al. The Asthma Control TestTM (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J 18, 41–49 (2009).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing